country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-182438

Copy Link Print Information

SDZ 51641

SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 91456-99-4
Formule: C₁₄H₂₀O₂
Masse moléculaire:220.31

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

SDZ 51641 Chemical Structure

CAS No.: 91456-99-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vivo

SDZ 51641 (70-100 μmol/kg; p.o.; days 1-11) reduces fatty acid oxidation and blood glucose levels without causing peripheral toxicity in 18-hour fasted normal Sprague‑Dawley rats and streptozotocin (STZ) (HY-13753)-induced diabetic rats^[1].
SDZ 51641 (700 µmol/kg; p.o.; once daily; for 28 days) reduces body weight and testicular weight, while increases liver weight, in normal Sprague Dawley rats compared with the control group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague‑Dawley rats treated STZ^[1]
Dosage:

70 µmol/kg
Administration:

p.o.; daily; 11 days
Result:

Inhibited hepatic fatty acid oxidation, decreased β‑hydroxybutyrate levels, reduced blood glucose production, and lowered serum glucose levels, while avoiding toxic effects on peripheral tissues such as the testes.

Chemical Information

CAS No. 91456-99-4
Masse moléculaire 220.31
Formule C₁₄H₂₀O₂
SMILES

CC(C=C1)=CC=C1C2(C(C)(C)C)OCCO2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Bebernitz GR, et al. Reduction in glucose levels in STZ diabetic rats by 4-(2,2-dimethyl-1-oxopropyl)benzoic acid: a prodrug approach for targeting the liver. J Med Chem. 2001;44(4):512-523. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis